Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Abstract Background Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and h...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrew James Boyle, Peter Ferris, Ian Bradbury, John Conlon, Manu Shankar-Hari, Angela J. Rogers, Cecilia M. O’Kane, Daniel F. McAuley
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-06-01
coleção:	Critical Care
Assuntos:	Acute respiratory distress syndrome Simvastatin Inflammasome Interleukin-18 Personalised medicine
Acesso em linha:	https://doi.org/10.1186/s13054-022-04025-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!